Background 4,4′-DMAR (4,4′-dimethylaminorex; "Serotoni") is a potent stimulant drug that has recently been associated with a number of fatalities in Europe. Over the last few years, online communities have emerged as important resources for disseminating levels of technical knowledge on novel psychoactive substances.
| INTRODUCTION
Internet use has become an unremarkable aspect of everyday life, providing a revolutionary tool to facilitate rapid interpersonal communication, exchange of ideas, opinions, and information on a range of issues, including recreational drugs (Wax, 2002) .
Overall, the web represents the most popular source of information about novel psychoactive substances (NPS) use (Nelson, Bryant, & Aks, 2014) . In this respect, Web fora are being extensively used as discussion areas (Orsolini, Papanti, Francesconi, & Schifano, 2015) . A forum moderator often oversees the communication activities, while facilitating the debate, and making decisions regarding the direction of threads. Apart from drug enthusiasts, fora members may include researchers, harm-reduction specialists, police officers, lawyers, physicians, journalists, and addiction specialists, all actively contributing to the debate (Drugs forum, 2013).
Although fora communities are virtual, these social groups can have consequential effects on many aspects of the member's behaviour (Kozinets, 2002) as the information being accessed may be Abbreviations: NPS, Novel psychoactive substances; ROA, Route of administration; SSRIs, Selective serotonin reuptake inhibitors misleading, or even dangerous, and particularly so for naïve users (Monahan & Colthurst, 2001 ).
With the increase in Web marketing of drugs available for purchase, online discussions have, however, become a reason for concern as they could lead to an increase in drug using levels (Soussan & Kjellgren, 2014) although playing a crucial part in raising interest about drugs (Griffiths, Sedefov, Gallegos, & Lopez, 2010 ).
| 4,4′-Dimethylaminorex (4,4′DMAR)
4,4′-DMAR ( Figure 1 ; IUPAC: 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine), is a synthetic substituted oxazoline derivative that contains two chiral centres and two racemic mixtures (i.e., (±)cis and (±)trans racemates). Previous analytical characterizations confirmed that the (±)cis racemate is the most available isomer in the market and the one involved in many deaths (Brandt, Baumann, et al., 2014; Brandt, King, Evans-Brown, 2014) . This stimulant drug is commonly advertised as "para-methyl-4-methylaminorex," "4-methyleuphoria," "4-methyl-U4Eu," "4-M-4-MAR," "4,4-dimethylaminorex,"
and "Serotoni."
It belongs to the NPS category, which encompasses a wide number of compounds widely marketed in the "real" and "virtual" world as legal substitutes for banned drugs and being sometimes more harmful than their parental compounds in terms of toxicity, adverse reactions, dependence, long-term effects (Schifano, Orsolini, Papanti, & Corkery, 2015) , fatalities Loi et al., 2015) , and psychiatric consequences (Martinotti et al., 2014) . 4,4′-DMAR was first detected in Europe in the Netherlands at the end of 2012, and by the first half of 2013, it had emerged in Denmark, Finland, Hungary, Poland, Romania, Sweden, and the United Kingdom (EMCDDA, 2014; EMCDDA, 2015) .
It is a research chemical most commonly sold over the Internet and head shops in the form of powder and tablets, usually labelled "Speckled Cherry" or "Speckled Cross" with a variety of logos, colours (e.g., white, pink, green, and blue), and shapes (EMCDDA, 2014) .
Both the tablets' and powder composition can be considerably different from a product to a product as they may contain 4,4′-DMAR alone or in combination with other psychoactive substances, including: synthetic cathinones, synthetic cannabinoids, benzofurans, and ethylphenidate. To date, the purity of the 4,4′-DMAR available on the drug market has not been reported (EMCDDA, 2015) .
As described by the EMCDDA (2015), seizures of products containing 4,4′-DMAR were reported in seven member states (Denmark, Finland, Hungary, the Netherlands, Romania, Sweden, and the United Kingdom), with a preferential availability of this substance in the Hungarian drug market.
In some cases, 4,4′-DMAR is offered on the illicit market as "ecstasy" and "amphetamine"; therefore, users may not always be aware of the associated health risks (EMCDDA, 2015) .
Because of serious adverse effects reported, including fatal intoxications entirely caused by (±)cis-4,4′-DMAR, this drug was banned in the United Kingdom, being placed in Schedule 1 (ACMD, 2014) 
| Pharmacology
(±)Cis-4,4′-DMAR is a monoamine-releasing agent that displays high potency at all three monoamine transporters. According to some pharmacodynamics studies, this compound was found to show equivalent potency at the dopamine and norepinephrine transporters and greater potency at the serotonin transporter, in comparison with d-amphetamine and aminorex (Brandt, Baummann, et al., 2014) .
In another study performed on rat brain synaptosomes, the monoamine releasing activity of (±)cis-4,4′-DMAR and (±)trans-4,4′-DMAR isomers was compared to that of 3,4-methylenedioxymethamphetamine (MDMA). Both cis-4,4′-DMAR and trans-4,4′-DMAR were found to be stronger than MDMA as releasing agents at the dopamine and norepinephrine transporters.
Concerning the activity at serotonin transporter, (±)cis-4,4′-DMAR acted as a fully effective releasing agent, whereas (±)trans-4,4′-DMAR acted as a fully efficacious uptake blocker (McLaughlin et al., 2014) .
Additionally, our unpublished data obtained using PreADMET online server (https://preadmet.bmdrc.kr/) indicate that 4,4′-DMAR has similar predicted blood brain barrier permeability as MDMA.
To date, no published data are available on the pharmacokinetics of 4,4′-DMAR in animals or humans and no metabolites of this substance have been detected up to now (EMCDDA, 2015).
| Fatalities and adverse effects
In December 2012, 4,4′-DMAR was first detected in fatalities reported from Sweden, followed by Denmark, Finland, Hungary, Romania, Sweden, France, and the United Kingdom (EMCDDA, 2015) .
Since October 2013, thirty-eight 4,4′-DMAR-related deaths have been identified in the United Kingdom (e.g., 36 in Northern Ireland, 1
in Scotland, and 1 in England); 8 in Hungary; and 1 in Poland in July 2013 (ACMD, 2014; Cosbey et al., 2014; EMCDDA, 2015; Shropshire Star, 2016) .
In all 47 cases, the 4,4′-DMAR presence, either alone or in combination with remaining recreational drugs (e.g., cocaine, amphetamines, cannabis, benzodiazepines, antidepressants, second-generation antipsychotics, opioids, and synthetic cathinones), was confirmed at postmortem (ACMD, 2014; EMCDDA, 2015). Additionally, the risk of experiencing a serotonergic syndrome may be increased by the association of 4,4′-DMAR with compounds affecting either the serotonin release (e.g., MDMA or ecstasy) or its reuptake, such as the selective serotonin reuptake inhibitors (SSRIs), (McLaughlin et al., 2014) .
We aimed here at reviewing the literature relating to 4,4′-DMAR intake. Furthermore, we aimed at describing, through an assessment of related anecdotal online reports, a range of clinical pharmacological issues to its misusing issues potential.
| METHODS
To identify peer-reviewed papers and online reports commenting on 4,4′-DMAR misuse issues, we performed a comprehensive search on the Embase, Scopus; Google Scholar, and Pubmed/Medline databases using the following key words: (4,4′-DMAR) AND (abuse OR misuse OR poisoning OR dependence OR addiction). No language or time restrictions were placed on the electronic search; focus was on both preclinical and clinical data and covered the period up to November 15, 2016.
To identify information on 4,4′-DMAR misusers' first-hand experiences, we carried out a qualitative/observational, that is, netnographic, approach on selected websites. In doing so, between
March and October 2016, a range of qualitative Google searches was carried out, in English, using key words such as "4,4′-DMAR and abuse," "4,4′-DMAR and misuse"; "4,4′-DMAR and experience"; "Serotoni and forum"; "Speckled Cherry forum"; "Speckled Cross forum"; "Para-Methyl-4-Methylaminorex forum"; "4-methyl-euphoria forum"; "4-methyl-U4Eu forum"; "4,4-dimethylaminorex forum."
The first two pages/20 hits per keyword (e.g., 60 per language; 120 links) were considered. A number of websites were subsequently excluded, because not relevant; being duplicates; or requiring a registration or payment procedure.
A total of six sites hosting forum activity around 4,4′-DMAR use were identified: 3 | RESULTS
| Literature identification and analysis
The comprehensive literature search led to the identification of 13 peer-reviewed papers and 3 reports (ACMD, 2014; EMCDDA, 2014; EMCDDA, 2015) focusing on 4,4′-DMAR use, which were critically analysed.
Published information on ROAs suggests that nasal insufflation and oral consumption practices are the most widely used followed by inhalation and injection (ACMD, 2014; EMCDDA, 2014; EMCDDA, 2015; Cosbey et al., 2014; Coppola & Mondola, 2015; Glanville, Dargan, & Wood, 2015; Hentig, 2016 ).
Oral doses were described ranging from 10 to 200 mg, although the insufflated ones vary from 10 to 65 mg (ACMD, 2014; Coppola & Mondola, 2015; EMCDDA, 2014; EMCDDA, 2015; Glanville et al., 2015; Hentig, 2016; Nizar, Dargan, & Wood, 2015) .
Oral consumption was reported to be commonly practiced by directly ingesting tablets or powder or by swallowing powder previously wrapped in cigarette papers ("bombing"; ACMD, 2014; Coppola & Mondola, 2015; Cosbey et al., 2014; EMCDDA, 2014; EMCDDA, 2015; Glanville et al., 2015) .
Commonly reported desired effects include euphoria, increased sociability and energy, alertness, and increased confidence; whereas untoward effects vary from increased heart rate, hyperthermia, sweat- The use of a range of sedatives and anxiolytics was reported as a common practice to reverse 4,4′-DMAR long-lasting stimulants' effects (12-16 hr; Glanville et al., 2015; .
Desired and untoward effects were described to be comparable to those observed with other stimulant-type drugs (e.g., MDMA, mephedrone) characterized by similar pharmacological properties (Brandt, Baummann, et al., 2014; McLaughlin et al., 2014; Schifano et al., 2015 Schifano et al., , 2016 Hentig, 2016; Lucchetti, Marzo, Di Clemente, Cervo, & Gobbi, 2016) .
Combination with other drugs (e.g., synthetic cathinones, amphetamines, and cocaine) has been widely reported and accounted for several toxicity events (e.g., cardiovascular effects, psychotic symptoms, and agitation hyperthermia) and fatalities (ACMD, 2014; Berg, 2016; Brandt, King, et al., 2014; Coppola & Mondola, 2015; Cosbey et al., 2014; EMCDDA, 2014; EMCDDA, 2015; Glanville et al., 2015; Hentig, 2016) .
Social cohesion, support, and harm-reduction advice have been also widely described among a range of NPS users (Soussan & Kjellgren, 2014) .
| Self-reported ROAs and dosages
Dosages and ROAs were found to be a widely debated topic of discussion. Overall users tended to specify doses, frequency of redosing, and the combination of different ROAs to achieve the optimal "high 
| Self-reported desired and untoward effects
Intensity and duration of the "positive" effects were widely reported;
70% (14/20) of users described a range of positive effects including stimulation, energy increase, euphoria, relaxation, increased sociability, empathy, disinhibition, and arousal ( Figure 2) .
By contrast, a range of adverse effects was described by 55% of users (11/20) and included hallucinations, altered perceptions, insomnia, queasiness, jaw clenching or tension or bruxism, blurry vision, nystagmus, psychosis, confusion, nausea, sweatiness, increased heart rate, and hyperthermia ( Figure 3 ).
The effects of 4,4′-DMAR were compared with those associated with other stimulant (e.g., 4FA, MDMA, 6-APB, APB, 3-MMC, 4-MMC, MDPV a-PVP, 4-MMA, and MDMA) intakes by 50% of the users (10/20). Comments included "Way better than cathinones! … it was also way way better than 4-FA which never really felt serotonergic to me"; … "It definitely felt stronger than any of my experiences on 6-APB though"; … "I found it to be a very nice experience, somewhat comparable to 3-MMC but a lot longer lasting and thus with a lot less craving" (Figure 3 ).
| Association with other recreational drugs
Some 30% (6/20) of users used 4,4′-DMAR with other drugs, especially alcohol (66%; 4/6); 6-APB (17%; 1/6); and phenylpiracetam (17%, 1/6; Figure 3 ).
Some users described a potentiation of 4,4′-DMAR effects while on alcohol ("definitely potentiated with alcohol"); and a feeling of "head clearness" ("Normally I would become sloppy and hazy with alcohol, but this was clear and fresh"). Finally, to cope with social anxiety issues, 4,4′-DMAR was associated with either alcohol or 6-APB.
| Medication(s) self-administered to revert 4,4′-DMAR action
Because 4,4′-DMAR stimulant effects seemed to be quite long lasting, some 20% of users (4/20) stated that they had used sedatives or anxiolytics (e.g., diazepam, zolpidem, trazodone, baclofen, flubromazepam, and etizolam; Figure 3 ).
| Overall impression
Some 50% (10/20) of fora users provided their peers with either a positive or a negative summary of their 4,4′-DMAR personal experiences, hence to promote or denigrate the use of this drug (Figure 4) . Indeed, most of them described their experience as "awesome," "enjoyable,"
"nice," "clean," and "comfortable" although others considered it "disappointing." Other users described their experience using technical language that involved a reference to the molecule's pharmacodynamics ("I really liked the dopamine-serotonin activation ration"); pharmacokinetics ("… a biphasic effect with a stimulation predominant on the side end … residual stimulation the day after"); or addictive liability levels ("significative addictive potential").
Overall, some users appeared enthusiastic ("I think it's the most beautiful, awesome stimulant I've ever tried" … "to me this feels like a product the market has been seriously lacking for a long time").
| Harm-reduction advice
Some fora discussions identified here were characterized by a general concern for safety, with some 30% (6/20) of users providing a range of advice, including avoiding concurrent ingestion of other drugs both on the intake day and for a few days after 4,4′-DMAR use; being careful about both the dosage self-administered and tendency to redosing, although considering the 4,4′-DMAR intensity of the psychoactive effects ("this is not a functional/nootropic stimulant, this is a more potent version of MDMA/APB"; Figure 4 ).
| DISCUSSION
4,4′-DMAR popularity in a range of different countries may well be related to both its significant psychoactive effects and the current intense Web-based marketing activities (EMCDDA, 2014). "hallucinogens" (including compounds such as 25I-and 25C-NBoMe, responsible for acute and chronic toxicities, according to their ability to act at the level of the serotoninergic system; Bersani et al., 2014) .
The public health risks related to 4,4′-DMAR use may be associated with a range of factors, including drug availability; quality and purity; levels of risk awareness amongst users; and potential combination of this drug with other substances (e.g., entactogens, stimulants, and/or depressants including alcohol; EMCDDA, 2014; EMCDDA, 2015). This tendency was already observed with other substances, such as 2C-T-7, a stimulant drug that rapidly disappeared from the cyber market after control legislation (Schifano et al., 2005) . However, this does not excluded the possibility of a move of 4,4′-DMAR-related illegal activities into the "deep Web," as already observed with other controlled substances . Moreover, the fall noted in deaths involving this molecule in 2015 (Corkery, 2016 ) may be due, in part, to the control of this substance. Equally, the fall may be due to fewer individuals using it following the bad reputation it received because of the sudden outbreaks of these severe adverse effects.
Overall, fora users mostly ingested 4,4′-DMAR powder and pellets, at dosages (e.g., 10-120 mg) consistent with previous reports (ACMD, 2014; EMCDDA, 2014), although vaping and snorting ROAs were at times preferred, with multiple redosing practice being described as quite a popular approach.
Most of the 4,4′-DMAR fora enthusiasts described here seemed to present with a previous history of drug misuse, although possessing large levels of technical or pharmacological knowledge regarding NPS and 4,4′-DMAR in particular, hence, well resembling the classical or standard e-psychonauts description.
The present report seems to confirm that 4,4′-DMAR is a popular recreational drug that, similarly to remaining stimulants, is associated with feelings of stimulation, euphoria, energy, alertness, and increasing confidence. The powerful "prosocial" effects (e.g., increased empathy, feelings of friendliness, interpersonal closeness, and openness) were here particularly emphasized (EMCDDA, 2014) . Related stimulant effects seemed to be characterized by a significant lag time, peaking in 2-5 hr but were long lasting (e.g., 12-16 hr) as well (Glanville et al., 2015) .
Consistent with previous studies (Glanville et al., 2015) , untoward effects were here described in some 55% of users, starting from the minimal (e.g., 5 mg) dosage and included nausea, dysphoria, agitation, confusion, aggression, sweating, increased heart rate, hyperthermia, dilated pupils, psychosis, hallucinations, insomnia, jaw clench or jaw tension or bruxism, blurry vision, and nystagmus. The 4,4′-DMAR pharmacodynamics profile may be broadly similar to that of other stimulants. However, because of both the intensity and the long duration of its effects, the 4,4′-DMAR intake may be a reason of particular concern, and especially so if the molecule, as here described by 30% of users, is ingested in combination with remaining serotonergic or dopaminergic compounds (Coppola & Mondola, 2015) .
These peculiar clinical pharmacological characteristics may help in explaining the disturbingly high rate of 4,4′-DMAR fatalities observed over a relatively short time in the EU and especially in Northern Ireland (EMCDDA, 2014) .
To counteract the long-lasting stimulant effects, we find that it is of interest to note that some 20% of users here allegedly selfadministered with a range of sedatives, including designer or "exotic"
benzodiazepines . In this way, users were arguably adding further health risks to the already risky practice of ingesting a powerful, but virtually unknown to the medical literature, stimulant such as 4,4′-DMAR.
| Limitations
There are a number of possible limitations of this study; a multilingual analysis of a larger sample of websites could have provided better levels of information. Furthermore, only publicly available websites or fora were monitored here, and further data of interest could possibly have been identified by the analysis of the deep Web and "dark net" materials . We made no 4,4′-DMAR purchase attempts; hence, one could argue about the product content or dosage being delivered. Overall, anecdotal reports are only partially reliable, and it may be inappropriate to trust information obtained from the internet without independent verification. Additionally, there is no certainty that multiple threads or posts were generated by different individuals, as it is not unusual that people can access the fora multiple times with different pseudonyms.
Because very few peer-reviewed papers relating to 4,4′-DMAR misuse issues were identified, the present conclusions mainly relied on sources (e.g., websites) that are characterized by levels of unreliabil- Further analyses should be undertaken to better draft a risk profile for this drug. As with any centrally active drug, physicians should carefully evaluate patients for history of drug abuse and observe them for signs of any products' , including 4,4′-DMAR, misuse. Additionally, prevention strategies should be developed and better public awareness levels should be promoted.
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